Established in 2003 by Prof. Raymond Kaempfer and Dr. Gila Arad from the Faculty of Medicine at the Hebrew University, Atox Bio is a clinical stage biotechnology company that develops novel immunemodulators in areas of major unmet need with a focus on critical care.
AB103, Atox Bio’s lead product, is being developed for severe infections in critically ill patients . AB103 completed a phase 2 study in patients with Necrotizing Soft Tissue Infections (NSTI). Results demonstrated that patients treated with AB103 had a meaningful improvement across multiple end points. A phase 3 study will begin in 2015.
AB103 was granted Fast Track status and Orphan Drug designation from the FDA as well as Orphan Medicinal Product designation from the European Commission.
Atox Bio's investors include SR One, OrbiMed and Lundbeckfond Ventures.
AB103 development is supported by a contract from BARDA.
Pre-clinical research is conducted in the areas of other severe infections and organ injury.